| Name | Title | Contact Details |
|---|
Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.
Enzon Pharmaceuticals Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Nines is a dynamic team applying world-class ML and AI expertise to the field of medicine.
Zygote is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.